Injection site reaction: FDA reporting patterns
67,712 FDA FAERS reports mention Injection site reaction. 13,057 reports have a serious outcome flag.
Medicines named as suspect
- Etanercept: 20,869 reports
- Adalimumab: 7,472 reports
- Dupilumab: 4,955 reports
- Naltrexone: 4,398 reports
- Glatiramer: 3,701 reports
- Tirzepatide: 2,203 reports
- Interferon Beta-1a: 1,898 reports
- Ixekizumab: 1,765 reports
- Methotrexate: 1,751 reports
- Certolizumab Pegol: 1,534 reports
- Tocilizumab: 1,453 reports
- Abatacept: 1,283 reports
FAERS reports describe events reported after a medicine was taken. They do not prove that the medicine caused an event, measure how often a side effect occurs, or estimate personal risk.
Source: FDA FAERS via openFDA. FAERS data through 2026-06-30. Sources, methods, and limitations.